Tufia C. Haddad - Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota.

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 11 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Transforming the oncology data paradigm by creating, capturing, and retrieving structured cancer data at the point of care: A Mayo Clinic pilot

Amye J Tevaarwerk, Dhauna Karam, Clare A Gatten, Elizabeth S Harlos,Matthew J Maurer, Karthik V Giridhar,Tufia C Haddad, Steven R Alberts,Sara J Holton, Abigail Stockham, Konstantinos Leventakos,Joleen M Hubbard,

Cancer (2024)

引用0浏览0WOS引用

Can dobutamine stress echocardiography (dse) be used to predict cardiovascular outcomes 20 years after chest radiotherapy

Diana B. Collantes-Hoyos,Rafael Toro-Manotas, Sebastian Santos-Patarroyo, Andres E. Daryanani, Carolina Ricaurte-Carmona, Enrique J. Alvirez Gonzalez, Eduardo Tellez Garcia, Jenna Hoppenworth,Jamie Carroll, Lori Thicke,Deanne Smith,Kathryn Ruddy,

Journal of the American College of Cardiologyno. 13 (2024): 2670

引用0浏览0引用

Association of anthracyclines with major adverse cardiovascular events (mace) in patients treated for breast cancer or lymphoma after 30 years of follow up

Eduardo Tellez Garcia, Diana B. Collantes-Hoyos, Carolina Ricaurte-Carmona, Andres E. Daryanani, Enrique J. Alvirez Gonzalez, Maria Gomez,Carolyn Larsen,Christopher Scott,Joerg Herrmann,James R. Cerhan,Tufia Haddad,Carrie A. Thompson,

Journal of the American College of Cardiologyno. 13 (2024): 2504

引用0浏览0引用

Even the presence of minimal changes in regional wall motion abnormalities with exercise stress echocardiography predicts MACE and all-cause mortality in patients with previous chest radiotherapy

R. Toro Manotas, S. Santos Patarroyo, A. Daryanani Acevedo, D. Collantes, C. Ricaurte,J. L. Carroll, J. E. Hoppenworth, L. A. Thicke,D. R. Smith,C. L. Klassen,T. C. Haddad,P. P. Peethambaram,

European Heart Journalno. Supplement_2 (2023)

引用0浏览0引用

Impact of BMI in Patients With Early Hormone Receptor–Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial